AR107220A1 - Conjugados péptido-oligonucleótido - Google Patents
Conjugados péptido-oligonucleótidoInfo
- Publication number
- AR107220A1 AR107220A1 ARP160103839A ARP160103839A AR107220A1 AR 107220 A1 AR107220 A1 AR 107220A1 AR P160103839 A ARP160103839 A AR P160103839A AR P160103839 A ARP160103839 A AR P160103839A AR 107220 A1 AR107220 A1 AR 107220A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- independently
- case
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un conjugado péptido-oligómero de fórmula (1) o una sal farmacéuticamente aceptable de este, donde R³ Se selecciona entre OH, -N(H)CH₂C(O)NH₂, -N(C₁₋₆-alquil)CH₂C(O)NH₂, un compuesto de fórmula (2) y un compuesto de fórmula (3); R⁵ es -C(O)(O-alquil)ˣOH, donde x es 3 - 10 y cada grupo alquilo es, independientemente en cada caso, C₂₋₆-alquilo, o bien R⁵ se selecciona del grupo que consiste en -C(O)C₁₋₆-alquilo, tritilo, monometoxitritilo, -(C₁₋₆-alquil)R⁶, -(C₁₋₆-heteroalquil)-R⁶, aril-R⁶, heteroaril-R⁶, -C(O)O-(C₁₋₆-alquil)-R⁶, -C(O)O-aril-R⁶, -C(O)O-heteroaril-R⁶ y R¹²; R⁶ se selecciona entre OH, SH y NH₂, o bien R⁶ es O, S o NH y está unido covalentemente a un soporte sólido; R¹ es, independientemente en cada caso, OH, -NR⁷R¹² o -NR⁷R⁸; cada R⁷ y R⁸ es, independientemente en cada caso, H o -C₁₋₆-alquilo; R² se selecciona, independientemente en cada caso, del grupo que consiste en H, una nucleobase y una nucleobase funcionalizada con un grupo químico protector, donde la nucleobase, independientemente en cada caso, comprende un anillo heterocíclico C₃₋₆ seleccionado entre piridina, pirimidina, triazinano, purina y deaza-purina; z es 8 - 40; R⁴ se selecciona entre H, -C₁₋₆-alquilo, -C(O)C₁₋₆-alquilo, bencilo, estearilo, tritilo, monometoxitritilo, dimetoxitritilo, trimetoxitritilo, un compuesto de fórmula (4) y R¹²; R⁹ es -C(O)(CH₂)₆C(O)- o -C(O)(CH₂)₂S₂(CH₂)₂C(O)-; R¹⁰ es -(CH₂)₂OC(O)N((CH₂)₆N(H)C(=NH)NH₂)₂; R¹¹ se selecciona entre OH y -NR⁷R⁸; R¹² se selecciona del grupo que consiste en el grupo de fórmulas (5); n es 1, 2, 3, 4, 5, 6, 7, 8, 9 ó 10; p es 2, 3, 4 ó 5; R¹³ es un enlace o se selecciona del grupo que consiste en el grupo de fórmulas (6); R¹⁵ y R¹⁹ se seleccionan, independientemente en cada caso, del grupo que consiste en H, -C₁₋₄-alquilo, -CH(-C₁₋₄-alquilo)₂ y -(CH₂)₃NH-C(=NH)-NH₂; t y w son, independientemente en cada caso, 2, 3, 4 ó 5; R¹⁴ se selecciona del grupo que consiste en el grupo de fórmulas (7); R¹⁷ es H o -C₁₋₄-alquilo; R²⁰ se selecciona del grupo que consiste en H, -C₁₋₄-alquilo, -CH(-C₁₋₄-alquilo)₂ y -(CH₂)₃NH-C(=NH)-NH₂; v y q son, independientemente en cada caso, 2, 3, 4 ó 5; R¹⁶ se selecciona del grupo que consiste en el grupo de fórmulas (8); R²¹ y R²² son, independientemente en cada caso, H o -C₁₋₄-alquilo; R¹⁸ se selecciona del grupo que consiste en H, -C(O)C₁₋₆-alquilo, bencilo y estearilo; r es 1, 2, 3, 4, 5, 6, 7, 8 ó 9; y y u son, independientemente en cada caso, 2, 3, 4 ó 5; con la condición de que se cumpla una sola de las siguientes condiciones: (i) que R¹ sea NR⁷R¹², (ii) que R⁴ sea R¹² o (iii) que R³ sea un compuesto de fórmula (9). Reivindicación 70: Un método para tratar un trastorno en el sistema nervioso central, una enfermedad muscular, una infección viral o una infección bacteriana en un sujeto que lo necesita, que comprende administrarle al sujeto un conjugado péptido-oligómero de cualquiera de las reivindicaciones 1 - 69. Reivindicación 74: El método de la reivindicación 70, donde el trastorno en el sistema nervioso central es la atrofia muscular espinal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267723P | 2015-12-15 | 2015-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107220A1 true AR107220A1 (es) | 2018-04-11 |
Family
ID=59057789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103839A AR107220A1 (es) | 2015-12-15 | 2016-12-15 | Conjugados péptido-oligonucleótido |
Country Status (15)
Country | Link |
---|---|
US (1) | US20190030176A1 (es) |
EP (1) | EP3389719B1 (es) |
JP (1) | JP2018538302A (es) |
KR (1) | KR20180088874A (es) |
CN (1) | CN108472504A (es) |
AR (1) | AR107220A1 (es) |
AU (1) | AU2016372026A1 (es) |
BR (1) | BR112018012237A2 (es) |
CA (1) | CA3006748A1 (es) |
EA (1) | EA201891419A1 (es) |
ES (1) | ES2901772T3 (es) |
IL (2) | IL259587A (es) |
MX (1) | MX2018007307A (es) |
TW (1) | TWI740866B (es) |
WO (1) | WO2017106304A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102530865B1 (ko) * | 2020-09-09 | 2023-05-10 | 연세대학교 산학협력단 | 자기조립 고리형 펩티드-올리고뉴클레오티드 복합체 및 이의 제조방법 |
WO2023034515A2 (en) * | 2021-09-03 | 2023-03-09 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
WO2023070086A1 (en) * | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2024016003A2 (en) | 2022-07-14 | 2024-01-18 | The Broad Institute, Inc. | Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
AU5698186A (en) | 1985-03-15 | 1986-10-13 | Summerton, J. | Polynucleotide assay reagent and method |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP2004500438A (ja) * | 2000-04-14 | 2004-01-08 | アルニス バイオサイエンシーズ, インコーポレイテッド | 高親和性のペプチド含有ナノ粒子 |
AU2002237684A1 (en) * | 2000-11-27 | 2002-06-03 | University Of Maryland, Baltimore | Methods of synthesizing and using derivatives of (2-(2-aminoethoxy)ethoxy) acetic acid |
US20070107072A1 (en) * | 2003-11-07 | 2007-05-10 | Peter Carmeliet | Transgenic amphibian models for lymphatic vessel development |
US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
EP2431467A3 (en) * | 2005-11-17 | 2012-05-02 | Board Of Regents, The University Of Texas | Modulation of gene expression by oligomers targeted to chromosomal DNA |
US8658608B2 (en) * | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
JP2009519033A (ja) * | 2005-12-16 | 2009-05-14 | ディアト | 核酸を細胞に送達するための細胞貫通ペプチド結合体 |
US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
MX2010004955A (es) | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Metodo de sintesis de oligomeros de morfolina. |
US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
US20110189692A1 (en) * | 2008-04-30 | 2011-08-04 | Novartis Ag | Assay for pathogenic conformers |
EP2623507B1 (en) | 2010-09-30 | 2016-11-02 | Nippon Shinyaku Co., Ltd. | Morpholino nucleic acid derivative |
AU2012223237A1 (en) * | 2011-03-02 | 2013-05-02 | Groove Biopharma Corporation | Enhanced biodistribution of oligomers |
EA202090338A1 (ru) * | 2011-11-18 | 2021-04-30 | Сарепта Терапьютикс, Инк. | Функционально-модифицированные олигонуклеотиды и их субъединицы |
TWI677350B (zh) * | 2012-09-25 | 2019-11-21 | 美商健臻公司 | 治療強直性肌失養症之經胜肽連結之嗎啉基反義寡核苷酸 |
NZ631289A (en) * | 2013-03-15 | 2017-08-25 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
BR112017018383B1 (pt) * | 2015-02-27 | 2023-04-25 | Murdoch University | Compostos anti-sentido que induzem a inclusão de éxon2, composições farmacêuticas que compreendem ditos compostos e usos dos mesmos para tratar doença de armazenamento de glicogênio tipo ii |
-
2016
- 2016-12-14 JP JP2018531210A patent/JP2018538302A/ja active Pending
- 2016-12-14 AU AU2016372026A patent/AU2016372026A1/en not_active Abandoned
- 2016-12-14 EP EP16876554.3A patent/EP3389719B1/en active Active
- 2016-12-14 US US16/061,971 patent/US20190030176A1/en not_active Abandoned
- 2016-12-14 EA EA201891419A patent/EA201891419A1/ru unknown
- 2016-12-14 CA CA3006748A patent/CA3006748A1/en not_active Abandoned
- 2016-12-14 KR KR1020187018470A patent/KR20180088874A/ko unknown
- 2016-12-14 ES ES16876554T patent/ES2901772T3/es active Active
- 2016-12-14 CN CN201680074252.6A patent/CN108472504A/zh active Pending
- 2016-12-14 BR BR112018012237A patent/BR112018012237A2/pt not_active IP Right Cessation
- 2016-12-14 WO PCT/US2016/066595 patent/WO2017106304A1/en active Application Filing
- 2016-12-14 MX MX2018007307A patent/MX2018007307A/es unknown
- 2016-12-15 AR ARP160103839A patent/AR107220A1/es unknown
- 2016-12-15 TW TW105141658A patent/TWI740866B/zh not_active IP Right Cessation
-
2018
- 2018-05-24 IL IL259587A patent/IL259587A/en unknown
-
2021
- 2021-07-11 IL IL284753A patent/IL284753A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2901772T3 (es) | 2022-03-23 |
WO2017106304A1 (en) | 2017-06-22 |
JP2018538302A (ja) | 2018-12-27 |
CA3006748A1 (en) | 2017-06-22 |
EP3389719A4 (en) | 2019-07-17 |
TW201728341A (zh) | 2017-08-16 |
US20190030176A1 (en) | 2019-01-31 |
AU2016372026A1 (en) | 2018-06-21 |
EA201891419A1 (ru) | 2019-01-31 |
EP3389719A1 (en) | 2018-10-24 |
MX2018007307A (es) | 2019-03-14 |
KR20180088874A (ko) | 2018-08-07 |
IL259587A (en) | 2018-07-31 |
EP3389719B1 (en) | 2021-11-17 |
BR112018012237A2 (pt) | 2018-12-04 |
CN108472504A (zh) | 2018-08-31 |
IL284753A (en) | 2021-08-31 |
TWI740866B (zh) | 2021-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR107220A1 (es) | Conjugados péptido-oligonucleótido | |
RU2017139121A (ru) | Композиции для модулирования экспрессии c9orf72 | |
PH12018502606A1 (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
HRP20200042T1 (hr) | Suprotne nukleinske kiseline za uporabu u liječenju duchennove mišićne distrofije | |
AR093308A1 (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
AR111247A1 (es) | Compuestos de dinucleótidos cíclicos modificados | |
AR103265A1 (es) | Compuestos de azolina sustituidos con un sistema de anillos condensado | |
AR108697A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
EA201992601A1 (ru) | Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak | |
BR112018006292A2 (pt) | ?composição fungicida para uso agrícola e hortícola? | |
WO2016096174A8 (en) | Cyclic dinucleotides for cytokine induction | |
AR065439A1 (es) | Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv. | |
EA201991144A1 (ru) | ЗАМЕЩЕННЫЕ ПИРИДО[3,4-b]ИНДОЛЫ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ХРЯЩЕВОЙ ТКАНИ | |
EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
RU2018104725A (ru) | Феноксигалогенфениламидины и их применение в качестве фунгицидов | |
AR103266A1 (es) | Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados | |
EA202091530A1 (ru) | Диазаиндольные соединения | |
EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
RU2019130898A (ru) | Композиции для модуляции экспрессии атаксина 2 | |
RU2018113276A (ru) | Антисмысловая нуклеиновая кислота | |
AR096461A1 (es) | Anticuerpos conjugados de fármacos | |
AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
BRPI0407055A (pt) | Derivados de isotiazol |